Evaluating linezolid dose regimens against methicillin‐resistant Staphylococcus aureus based on renal function in populations with different body weight
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13765
Abstract: Linezolid is an alternative first‐line agent for MRSA pneumonia. This study assessed whether dose adjustments of linezolid against methicillin‐resistant Staphylococcus aureus (MRSA) infections were needed based on renal function in populations with different body weight. read more here.
Keywords: methicillin resistant; based renal; staphylococcus aureus; function populations ... See more keywords